论文部分内容阅读
为探索Ｐ１６蛋白表达与非何杰金氏淋巴瘤（ＮＨＬ）的关系，作者应用免疫组化技术检测４５例非何杰金氏淋巴瘤、４例淋巴结反应性增生（ＲＨＬＮ）和６例脾脏标本中肿瘤抑制基因Ｐ１６蛋白的表达。结果显示：ＲＨＬＮ和脾的淋巴小结周围和窦周围的淋巴细胞部分呈Ｐ１６蛋白阳性表达，ＮＨＬ的Ｐ１６蛋白阳性表达率为３７．８％（１７／４５），其中低度恶性组为６６．７％（１０／１５），中度恶性组为３７．５％（６／１６），高度恶性组为７．１％（１／１４），ＮＨＬ的低度与高度恶性程度组间比较，差异有高度显著性（Ｐ＜０．０１），提示Ｐ１６蛋白可能是ＮＨＬ预后判定的一个重要指标。
To explore the relationship between P16 protein expression and non-Hodgkin’s lymphoma (NHL), the authors used immunohistochemistry to detect 45 cases of non-Hodgkin’s lymphoma, 4 cases of lymph node reactive hyperplasia (RHLN) and 6 cases of spleen specimens The tumor suppressor gene P16 protein expression. The results showed that: P16 protein was positively expressed in lymphocytes around lymph nodes and peri-sinusoids in RHLN and spleen, and the positive rate of P16 protein in NHL was 37.8% (17/45), among which the low-grade group was 66.7. % (10/15), moderately malignant group was 37.5% (6/16), and high-grade malignant group was 7.1% (1/14). There was a difference between the low-grade and high-grade malignancy groups of NHL. It was highly significant (P<0.01), suggesting that P16 protein may be an important indicator of prognosis of NHL.